Sign in
Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus
Journal article   Peer reviewed

Intravenous interferon during the anhepatic phase of liver retransplantation and prevention of recurrence of cholestatic hepatitis C virus

Paul Y Kwo, Romil Saxena, Oscar W Cummings, A Joseph Tector and Alfred Tector
Liver transplantation, Vol.13(12), pp.1710-1713
2007-12
PMID: 18044743

Abstract

Adult Antiviral Agents - administration & dosage Cholestasis, Intrahepatic - drug therapy Cholestasis, Intrahepatic - pathology Cholestasis, Intrahepatic - prevention & control Cholestasis, Intrahepatic - surgery Cholestasis, Intrahepatic - virology Drug Therapy, Combination Graft Rejection - drug therapy Graft Rejection - pathology Graft Rejection - prevention & control Graft Rejection - surgery Graft Rejection - virology Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C - complications Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - pathology Hepatitis C - prevention & control Hepatitis C - surgery Humans Infusions, Intravenous Interferon-alpha - administration & dosage Liver Cirrhosis - surgery Liver Cirrhosis - virology Liver Transplantation Male Middle Aged Polyethylene Glycols Recombinant Proteins Reoperation Ribavirin - administration & dosage RNA, Viral - blood Secondary Prevention Time Factors

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.125 Hepatitis
1.125.83 HCV
Web Of Science research areas
Gastroenterology & Hepatology
Surgery
Transplantation
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details